What's Happening?
Ferring Pharmaceuticals has released a new real-world case series demonstrating that re-induction with ADSTILADRIN (nadofaragene firadenovec-vncg) resulted in complete responses in 31% of patients with high-risk
BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) who did not respond to an initial dose. The study, presented at the 2026 American Urological Association Annual Meeting, included patients with carcinoma in situ (CIS), with or without papillary tumors. ADSTILADRIN is the first FDA-approved non-replicating intravesical gene therapy for this condition, administered every three months.
Why It's Important?
This development is crucial as it offers a potential new treatment pathway for patients with BCG-unresponsive NMIBC, a group with limited options. The findings suggest that re-induction with ADSTILADRIN could allow additional patients to achieve a complete response, potentially improving outcomes in a real-world setting. This could lead to broader adoption of ADSTILADRIN in clinical practice, providing hope for patients who have exhausted other treatment avenues.
What's Next?
Further studies are needed to confirm these findings and explore the long-term benefits of re-induction with ADSTILADRIN. The results could influence treatment guidelines and encourage more widespread use of this therapy in clinical settings. Ferring Pharmaceuticals may continue to gather real-world evidence to support the efficacy and safety of ADSTILADRIN, potentially leading to expanded indications or new therapeutic strategies.
